Results 51 to 60 of about 2,874 (159)

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity

Clinical and Translational Science, Volume 18, Issue 5, May 2025.
ABSTRACT The combination of vancomycin and piperacillin‐tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other ...
Congqin Chen, Rijing Zhou, Jie Fang, Jie Xiao   +3 more
wiley   +1 more source

Meropenem/Vaborbactam—A Mechanistic Review for Insight into Future Development of Combinational Therapies

Antibiotics
Beta-lactam antibiotics have been a major climacteric in medicine for being the first bactericidal compound available for clinical use. They have continually been prescribed since their development in the 1940s, and their application has saved an ...
Trae Hillyer, Woo Shik Shin
doaj   +1 more source

A review of antibiotic safety in pregnancy—2025 update

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen, Victoria Madonia, Christopher M. Bland, Kayla R. Stover, Lea S. Eiland, Julia Keating, Madeline Lemmon, P. Brandon Bookstaver, as part of the Southeastern Research Group Endeavor (SERGE‐45) research network   +8 more
wiley   +1 more source

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections [PDF]

Clinical Infectious Diseases, 2019
AbstractTwenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days.
Ryan K, Shields, Erin K, McCreary, Rachel V, Marini, Ellen G, Kline, Chelsea E, Jones, Binghua, Hao, Liang, Chen, Barry N, Kreiswirth, Yohei, Doi, Cornelius J, Clancy, M Hong, Nguyen   +10 more
openaire   +2 more sources

Epidemiology, Treatment, and Outcomes of Gram‐Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients

Clinical Transplantation, Volume 39, Issue 4, April 2025.
ABSTRACT Introduction Little is known about the epidemiology and management of gram‐negative bloodstream infections (GN‐BSIs) in patients after solid organ transplant (SOT). We describe epidemiology, treatment approaches, and outcomes in a subset of patients with SOT from a larger cohort with GN‐BSI. Methods This was a multicenter, retrospective cohort
Sarah B. Doernberg, Emily L. Heil, Suiyini Fiawoo, Jae Hyoung Lee, Sara E. Cosgrove, David M. Dobrzynski, Yihan Li, Ryan K. Shields, Emily S. Spivak, Erica J. Stohs, Pranita D. Tamma, Erin K. McCreary   +11 more
wiley   +1 more source

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Vaborbactam (formerly RPX7009) is a novel inhibitor of serine β-lactamases, including Ambler class A carbapenemases, such as KPCs. The current study evaluated the in vitro activity of the combination agent meropenem-vaborbactam against a global collection of 991 isolates of KPC-positive
Hackel, Meredith A., Lomovskaya, Olga, Dudley, Michael N., Karlowsky, James A., Sahm, Daniel F.   +4 more
openaire   +2 more sources

Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update

EFSA Journal, Volume 23, Issue 4, April 2025.
Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Ana Allende, Avelino Álvarez‐Ordóñez, Valeria Bortolaia, Sara Bover‐Cid, Alessandra De Cesare, Wietske Dohmen, Laurent Guillier, Lieve Herman, Liesbeth Jacxsens, Lapo Mughini‐Gras, Maarten Nauta, Jakob Ottoson, Fernando Pérez‐Rodríguez, Panagiotis Skandamis, Elisabetta Suffredini, Hector Argüello, Johan Bengtsson‐Palme, Alessandra Carattoli, Anke Kohlenberg, Dominique L. Monnet, Laurent Poirel, Beatriz Guerra, Raquel García‐Fierro, Ernesto Liébana, Sonagnon Martin Goudjihounde, Núria Ferrer‐Bustins, Hanne Rabbås, Luisa Peixe   +28 more
wiley   +1 more source

Innovative Wirkstoffe aus der antibakteriellen Forschung im Kampf gegen mikrobielle Resistenzen

Angewandte Chemie, Volume 137, Issue 10, March 3, 2025.
Dieser Artikel gewährt einen Überblick über in den letzten drei Jahrzehnten untersuchte antibakteriellen Wirkstoffe. Aspekte der Herkunft, der zellulären Targetstrukturen, des antibakteriellen Wirkspektrums und dem Nachweis der Wirksamkeit in Tierstudien werden zusammen mit aktuellen Entwicklungen beleuchtet.
Roderich D. Süssmuth, Marcel Kulike‐Koczula, Peng Gao, Simone Kosol   +3 more
wiley   +1 more source

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

Infection and Drug Resistance, 2022
Raghdaa Shrief,1 Amira H El-Ashry,2 Rasha Mahmoud,3 Rasha El-Mahdy2 1Medical Microbiology and Immunology Department, Faculty of Medicine, Damietta University, Damietta, Egypt; 2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura
Shrief R, El-Ashry AH, Mahmoud R, El-Mahdy R   +3 more
doaj  

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

Drugs, 2018
The article Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
openaire   +2 more sources